These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9362407)

  • 21. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
    Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group.
    Barth JD; Zonjee MM
    Can J Cardiol; 1992 Nov; 8(9):925-32. PubMed ID: 1486543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
    Sakamoto K; Sakamoto T; Ogawa H;
    Clin Ther; 2006 Jul; 28(7):1012-21. PubMed ID: 16990079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
    Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment.
    Takeshita M; Katsuragi Y; Kusuhara M; Higashi K; Miyajima E; Mizuno K; Mori K; Obata T; Ohmori R; Ohsuzu F; Onodera Y; Sano J; Sawada S; Tabata S; Tokimitsu I; Tomonobu K; Yamashita T; Yasukawa T; Yonemura A; Nakamura H
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):483-91. PubMed ID: 17964767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
    Sacks FM; Pasternak RC; Gibson CM; Rosner B; Stone PH
    Lancet; 1994 Oct; 344(8931):1182-6. PubMed ID: 7934538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
    Jukema JW; Zwinderman AH; van Boven AJ; Reiber JH; Van der Laarse A; Lie KI; Bruschke AV
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):425-30. PubMed ID: 8630669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
    MacMahon S; Sharpe N; Gamble G; Hart H; Scott J; Simes J; White H
    Circulation; 1998 May; 97(18):1784-90. PubMed ID: 9603532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial.
    Syvänne M; Taskinen MR; Nieminen ; Manninen V; Kesäniemi YA; Pasternack A; Nawrocki JW; Haber H; Frick MH
    Control Clin Trials; 1997 Feb; 18(1):93-119. PubMed ID: 9055055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.